Terms: = Head and neck cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
617 results:
1. Augmented ERO1α upon mtorC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11.
Wang Z; Zong H; Liu W; Lin W; Sun A; Ding Z; Chen X; Wan X; Liu Y; Hu Z; Zhang H; Li H; Liu Y; Li D; Zhang S; Zha X
J Exp Clin Cancer Res; 2024 Apr; 43(1):112. PubMed ID: 38610018
[TBL] [Abstract] [Full Text] [Related]
2. PQR309, a dual PI3K/mtor inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma.
Cao J; Zeng K; Chen Q; Yang T; Lu F; Lin C; Zhan J; Ma W; Zhou T; Huang Y; Luo F; Zhao H
Cell Death Dis; 2024 Mar; 15(3):237. PubMed ID: 38555280
[TBL] [Abstract] [Full Text] [Related]
3. Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights.
Papadakos SP; Argyrou A; Lekakis V; Arvanitakis K; Kalisperati P; Stergiou IE; Konstantinidis I; Schizas D; Koufakis T; Germanidis G; Theocharis S
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474224
[TBL] [Abstract] [Full Text] [Related]
4. PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral cancer Cells.
Yadav AK; Wang S; Shin YM; Jang BC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474118
[TBL] [Abstract] [Full Text] [Related]
5. Differential modulation of PI3K/Akt/mtor activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H
Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897
[TBL] [Abstract] [Full Text] [Related]
6. Different Impacts of DNA-PK and mtor Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells.
Klieber N; Hildebrand LS; Faulhaber E; Symank J; Häck N; Härtl A; Fietkau R; Distel LV
Cells; 2024 Feb; 13(4):. PubMed ID: 38391917
[TBL] [Abstract] [Full Text] [Related]
7. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
[TBL] [Abstract] [Full Text] [Related]
8. Artesunate-loaded solid lipid nanoparticles resist esophageal squamous cell carcinoma by inducing Ferroptosis through inhibiting the AKT/mtor signaling.
Xia Y; Tang Y; Huang Z; Ke N; Zheng Y; Zhuang W; Zhang Y; Yin X; Tu M; Chen J; Wang Y; Huang Y
Cell Signal; 2024 May; 117():111108. PubMed ID: 38369266
[TBL] [Abstract] [Full Text] [Related]
9. Deep response to a combination of mtor inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
10. GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
Zhang X; Zhang L; Wang B; Zhang X; Gu L; Guo K; Zhang X; Zhou Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):221-225. PubMed ID: 38279433
[TBL] [Abstract] [Full Text] [Related]
11. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Hanna GJ; Dharanesswaran H; Giobbie-Hurder A; Harran JJ; Liao Z; Pai L; Tchekmedyian V; Ruiz ES; Waldman AH; Schmults CD; Riella LV; Lizotte P; Paweletz CP; Chandraker AK; Murakami N; Silk AW
J Clin Oncol; 2024 Mar; 42(9):1021-1030. PubMed ID: 38252908
[TBL] [Abstract] [Full Text] [Related]
12. Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
Jagadeeshan S; Suryamohan K; Shin N; Mathukkada S; Boyko A; Melikhova D; Tsareva A; Yunusova L; Pravdivtseva E; Stupichev D; Shaposhnikov K; Peterson A; Bednyagin L; Shugaev-Mendosa E; Kessler L; Burrows F; Ho AL; Agrawal N; Pearson AT; Izumchenko E; Cole G; Elkabets M; Rosenberg AJ
Oral Oncol; 2024 Feb; 149():106688. PubMed ID: 38219706
[TBL] [Abstract] [Full Text] [Related]
13. Network pharmacology, molecular docking and experimental study of CEP in nasopharyngeal carcinoma.
Yang J; Qin L; Zhou S; Li J; Tu Y; Mo M; Liu X; Huang J; Qin X; Jiao A; Wei W; Yang P
J Ethnopharmacol; 2024 Apr; 323():117667. PubMed ID: 38159821
[TBL] [Abstract] [Full Text] [Related]
14. Phase I Study of mtorC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mtor/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
15. The effects of HPV oncoproteins on host communication networks: Therapeutic connotations.
Skelin J; Luk HY; Butorac D; Boon SS; Tomaić V
J Med Virol; 2023 Dec; 95(12):e29315. PubMed ID: 38115222
[TBL] [Abstract] [Full Text] [Related]
16. Cold atmospheric plasma sensitizes head and neck cancer to chemotherapy and immune checkpoint blockade therapy.
Wang Y; Mang X; Li D; Wang Z; Chen Y; Cai Z; Tan F
Redox Biol; 2024 Feb; 69():102991. PubMed ID: 38103343
[TBL] [Abstract] [Full Text] [Related]
17. Autophagy indicators in oral squamous cell carcinoma.
Pangarkar M; Wagh U; Pathak A
Pathology; 2024 Feb; 56(1):59-64. PubMed ID: 37981514
[TBL] [Abstract] [Full Text] [Related]
18. Enhancing nasopharyngeal carcinoma cell radiosensitivity by suppressing AKT/mtor via CENP-N knockdown.
Wu LZ; Zou Y; Wang BR; Ni HF; Kong YG; Hua QQ; Chen SM
J Transl Med; 2023 Nov; 21(1):792. PubMed ID: 37940975
[TBL] [Abstract] [Full Text] [Related]
19. head and neck cancer stem cell maintenance relies on mtor signaling, specifically involving the mechanistic target of rapamycin complexes 1 and 2 (mtorC1 and mtorC2).
Almeida LO; Silva LC; Emerick C; Amorim Dos Santos J; Castilho RM; Squarize CH
Arch Oral Biol; 2024 Jan; 157():105840. PubMed ID: 37939517
[TBL] [Abstract] [Full Text] [Related]
20. Plumbagin has an inhibitory effect on the growth of TSCC PDX model and it enhances the anticancer efficacy of cisplatin.
Xin Y; Jiang Q; Liu C; Qiu J
Aging (Albany NY); 2023 Nov; 15(21):12225-12250. PubMed ID: 37925175
[TBL] [Abstract] [Full Text] [Related]
[Next]
